Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy

Table 1

Baseline characteristics of patients.

	Age/sex	Comorbid conditions	Decitabine	EF 1^a	Biomarker	Test^b	EF 2^c	EF Δ^d
De et al. [6] (2012)	75 yrs/M	DM type II, DVT	2 cycles	35%	BNP: 259	Coronary angiogram	50% (after 7 days)	Yes
Our patient	71 yrs/F	HTN, Hep B, hypothyroidism	10 cycles	28%	Pro-BNP: 517	Nuclear stress test	28% (after 4 weeks) but with improvement in strain	No

^aBaseline left ventricular ejection fraction. ^bTest to rule out coronary artery disease. ^cRepeat left ventricular ejection fraction. ^dReversibility of ejection fraction. Note: both patients received decitabine as part of treatment for acute myeloid leukemia. Abbreviations: BNP: brain natriuretic peptide; DM: diabetes mellitus; DVT: deep vein thrombosis; EF: ejection fraction; HTN: hypertension; Hep B: hepatitis B; BNP units: pg/ml.